Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Habte A. Yimer"'
Autor:
Peter Hillmen, Barbara Eichhorst, Jennifer R. Brown, Nicole Lamanna, Susan M. O'Brien, Constantine S. Tam, Lugui Qiu, Maciej Kazmierczak, Keshu Zhou, Martin Šimkovič, Jiří Mayer, Amanda Gillespie-Twardy, Mazyar Shadman, Alessandra Ferrajoli, Peter S. Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Anders Österborg, Habte A. Yimer, Tommi Salmi, Meng Ji, Jessica Yecies, Adam Idoine, Kenneth Wu, Jane Huang, Wojciech Jurczak
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 41, iss 5
PURPOSE Zanubrutinib is a potent, irreversible next-generation Bruton tyrosine kinase (BTK) inhibitor designed to maximize BTK occupancy and minimize off-target kinase inhibition. We hypothesized that complete/sustained BTK occupancy may improve effi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cebead271e6234bf0b9f19719ee31aa4
https://ruj.uj.edu.pl/xmlui/handle/item/305371
https://ruj.uj.edu.pl/xmlui/handle/item/305371
Autor:
M.C. Liu, G.R. Oxnard, E.A. Klein, C. Swanton, M.V. Seiden, Minetta C. Liu, Geoffrey R. Oxnard, Eric A. Klein, David Smith, Donald Richards, Timothy J. Yeatman, Allen L. Cohn, Rosanna Lapham, Jessica Clement, Alexander S. Parker, Mohan K. Tummala, Kristi McIntyre, Mikkael A. Sekeres, Alan H. Bryce, Robert Siegel, Xuezhong Wang, David P. Cosgrove, Nadeem R. Abu-Rustum, Jonathan Trent, David D. Thiel, Carlos Becerra, Manish Agrawal, Lawrence E. Garbo, Jeffrey K. Giguere, Ross M. Michels, Ronald P. Harris, Stephen L. Richey, Timothy A. McCarthy, David M. Waterhouse, Fergus J. Couch, Sharon T. Wilks, Amy K. Krie, Rama Balaraman, Alvaro Restrepo, Michael W. Meshad, Kimberly Rieger-Christ, Travis Sullivan, Christine M. Lee, Daniel R. Greenwald, William Oh, Che-Kai Tsao, Neil Fleshner, Hagen F. Kennecke, Maged F. Khalil, David R. Spigel, Atisha P. Manhas, Brian K. Ulrich, Philip A. Kovoor, Christopher Stokoe, Jay G. Courtright, Habte A. Yimer, Timothy G. Larson, Charles Swanton, Michael V. Seiden, Steven R. Cummings, Farnaz Absalan, Gregory Alexander, Brian Allen, Hamed Amini, Alexander M. Aravanis, Siddhartha Bagaria, Leila Bazargan, John F. Beausang, Jennifer Berman, Craig Betts, Alexander Blocker, Joerg Bredno, Robert Calef, Gordon Cann, Jeremy Carter, Christopher Chang, Hemanshi Chawla, Xiaoji Chen, Tom C. Chien, Daniel Civello, Konstantin Davydov, Vasiliki Demas, Mohini Desai, Zhao Dong, Saniya Fayzullina, Alexander P. Fields, Darya Filippova, Peter Freese, Eric T. Fung, Sante Gnerre, Samuel Gross, Meredith Halks-Miller, Megan P. Hall, Anne-Renee Hartman, Chenlu Hou, Earl Hubbell, Nathan Hunkapiller, Karthik Jagadeesh, Arash Jamshidi, Roger Jiang, Byoungsok Jung, TaeHyung Kim, Richard D. Klausner, Kathryn N. Kurtzman, Mark Lee, Wendy Lin, Jafi Lipson, Hai Liu, Qinwen Liu, Margarita Lopatin, Tara Maddala, M. Cyrus Maher, Collin Melton, Andrea Mich, Shivani Nautiyal, Jonathan Newman, Joshua Newman, Virgil Nicula, Cosmos Nicolaou, Ongjen Nikolic, Wenying Pan, Shilpen Patel, Sarah A. Prins, Richard Rava, Neda Ronaghi, Onur Sakarya, Ravi Vijaya Satya, Jan Schellenberger, Eric Scott, Amy J. Sehnert, Rita Shaknovich, Avinash Shanmugam, K.C. Shashidhar, Ling Shen, Archana Shenoy, Seyedmehdi Shojaee, Pranav Singh, Kristan K. Steffen, Susan Tang, Jonathan M. Toung, Anton Valouev, Oliver Venn, Richard T. Williams, Tony Wu, Hui H. Xu, Christopher Yakym, Xiao Yang, Jessica Yecies, Alexander S. Yip, Jack Youngren, Jeanne Yue, Jingyang Zhang, Lily Zhang, Lori (Quan) Zhang, Nan Zhang, Christina Curtis, Donald A. Berry
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology
Background Early cancer detection could identify tumors at a time when outcomes are superior and treatment is less morbid. This prospective case-control sub-study (from NCT02889978 and NCT03085888) assessed the performance of targeted methylation ana
Autor:
Fergus J. Couch, Jingjing Gao, W.H. Wilson Tang, Spencer H. Shao, Oliver Venn, Mohan K. Tummala, Jessica M. Clement, Kathryn N. Kurtzman, Charles Swanton, Gina G. Chung, Habte A. Yimer
Publikováno v:
Journal of Clinical Oncology. 39:3072-3072
3072 Background: The Circulating Cell-free Genome Atlas study (CCGA; NCT02889978) previously demonstrated that a blood-based multi-cancer early detection (MCED) test utilizing cell-free DNA (cfDNA) sequencing in combination with machine learning coul
Autor:
Alok A, Khorana, Gerald A, Soff, Ajay K, Kakkar, Saroj, Vadhan-Raj, Hanno, Riess, Ted, Wun, Michael B, Streiff, David A, Garcia, Howard A, Liebman, Chandra P, Belani, Eileen M, O'Reilly, Jai N, Patel, Habte A, Yimer, Peter, Wildgoose, Paul, Burton, Ujjwala, Vijapurkar, Simrati, Kaul, John, Eikelboom, Robert, McBane, Kenneth A, Bauer, Nicole M, Kuderer, Gary H, Lyman, David, Seastone
Publikováno v:
The New England journal of medicine. 380(8)
Ambulatory patients receiving systemic cancer therapy are at varying risk for venous thromboembolism. However, the benefit of thromboprophylaxis in these patients is uncertain.In this double-blind, randomized trial involving high-risk ambulatory pati
Autor:
Ujjwala Vijapurkar, Habte A. Yimer, Ajay K. Kakkar, Alok A. Khorana, Gerald A. Soff, Theodore Wun, Hanno Riess, Robert D. McBane, Michael B. Streiff, Eileen M. O'Reilly, Howard A. Liebman, David A. Garcia, Peter Wildgoose, Paul Burton, Saroj Vadhan-Raj, Jai N. Patel, Nicole M. Kuderer, Gary H. Lyman, Simrati Kaul, Chandra P. Belani, John W. Eikelboom, Kenneth A. Bauer
Publikováno v:
Blood. 132:LBA-1
Background: Patients on systemic therapy for cancer are at varying risk for venous thromboembolism (VTE) and its consequences. Thromboprophylaxis is recommended in hospitalized medical and surgical cancer patients, but most VTE occurs in ambulatory c
Autor:
Carlos Becerra, Matthew Hitron, John L. Hays, Habte A. Yimer, Kimiko Kossler, Adrian Langleben, Donald A. Richards, Chiang Li, Agustin A. Garcia, Stephanie Hume, Fadi Braiteh, Youzhi Li, Gregory M. Cote, Colleen McCormick, S. Lau, William Jeffery Edenfield, Lynda D. Roman, Stephen Lane Richey
Publikováno v:
Journal of Clinical Oncology. 34:5578-5578
5578Background: Napabucasin (BBI-608, BB608) is a first-in-class cancer stemness inhibitor targeting the STAT3 pathway that has shown potent synergistic anti-tumor activity with paclitaxel in vivo....